Welcome to the Paragon Genomics Community

Paragon Genomics publications, interviews, and case studies provide up-to-date information about how target enrichment solutions are impacting the genomics community and precision medicine and research. Learn how Paragon Genomics technology is being applied to advance research with infectious disease, precision oncology, gene editing, inherited disease, and molecular breeding and genotyping.

Paragon Genomics

Areas of Interest

Omicron Sub-Lineage BA.5 and Recombinant XBB Evasion

Genomic malaria surveillance of antenatal care users detects reduced transmission following elimination interventions in Mozambique

The research outlines how genomic surveillance, notably using the Paragon Genomics CleanPlex Malaria NGS Panel, at antenatal care visits in Mozambique demonstrates a decline in malaria transmission following elimination efforts. It highlights the consistent genetic diversity and drug resistance between malaria parasites in pregnant women and children, noting a significant genetic diversity reduction in targeted areas, indicative of reduced parasite populations. This approach underscores the potential of advanced genomic tools in enhancing malaria control and eradication strategies.

Low-burden TP53 mutations represent frequent genetic events in CLL with an increased risk for treatment initiation

Test h3


Low-burden TP53 mutations represent frequent genetic events in CLL with an increased risk for treatment initiation

Low-burden TP53 mutations represent frequent genetic events in CLL with an increased risk for treatment initiation

Dr. Lazlo with fellow researchers performed a systematic study, delving into the significance of TP53 mutations in chronic lymphocytic leukemia (CLL) and their impact on chemo resistance. Leveraging Paragon Genomics' CleanPlex TP53 panel, they were able to identify 225 TP53 mutations in a real-world cohort of 991 patients with CLL, detecting somatic mutations with a frequency as low as 1%. The researchers were able to demonstrate that patients with sole low-burden TP53 variants represent more than 1/3 of patients with TP53 mutations and have an increased risk for treatment initiation, strengthening the need to redefine the threshold of TP53 variant reporting to below 10% in the routine diagnostic setting.

chronic lymphocytic leukemia

Detection of early seeding of Richter transformation in chronic lymphocytic leukemia

Prof. Campo published findings in Nature Medicine characterizing the genome of patients with Richter transformation (RT) of chronic lymphocytic leukemia (CLL).  They discovered mutational signatures and driver alterations linked in the process of cancer evolution, and mechanisms that drive RT. 77 of those mutations were identified by Paragon’s Custom UMI NGS panel, with multiple of them classified as high confidence and detected at 0.5% LOD or lower (<0.1%), in which background was detected at 2-3 or more fold less. The panel was applied in a longitudinal patient study to characterize these mutational profiles in the onset of RT as correlated to specific drug therapies.

Molecular and phenotypic diversity of CBL mutated juvenile myelomonocytic leukemia

Molecular and phenotypic diversity of CBL mutated juvenile myelomonocytic leukemia

Dr. Stieglitz with fellow researchers at UCSF performed a systematic study of CBL mutations in juvenile myelomonocytic leukemia (JMML) with a custom 26-gene assay powered by Paragon Genomics’ CleanPlex technology and used it to correlate mutational burden with potential therapeutic regimens. Researchers were able to discover somatically acquired CBL mutations for the first time in JMML at the known hotspot loci, which has helped clarify why the disease is highly diverse in presentation and overall outcome for patients with CBL mutations

Non-Small-Cell Lung Cancer Patients

Single Circulating-Tumor-Cell-Targeted Sequencing to Identify Somatic Variants in Liquid Biopsies in Non-Small-Cell Lung Cancer Patients

Dr. Mouadh Barbirou and fellow researchers at the University of Missouri publish their findings that single circulating tumor cells (CTCs) detected by liquid biopsy can offer a robust tool for molecular profiling of cancer. Single CTCs were isolated and processed from non-small-cell lung cancer (NSCLC) patients via the RareCyte platform and 65 genes were targeted and sequenced using Paragon’s CleanPlex OncoZoom Cancer Hotspot NGS Panel. Somatic variants, particularly mutations in functional domains of seven critical oncogenes/tumor suppressor genes were identified and confirmed shared mutational signatures between the NSCLC patients. The study highlights the clear potential of CTC single-cell genomics in the field of precision oncology and its clinical value for diagnostics and therapy management.

Identification and Characterization of Effusion Tumor Cells

Identification and Characterization of Effusion Tumor Cells (ETCs) From Remnant Pleural Effusion Specimens

Prof. Lowe from Stanford University along with colleagues from RareCyte, Inc performed a study to identify and characterize Effusion Tumor Cells (ETCs) from malignant pleural effusions in patients with metastatic lung adenocarcinoma. Pleural effusion specimens have not yet been routinely used for molecular testing because of their frequent low tumor fraction and sparse cellularity. In this study, researchers modified and applied a Circulating Tumor Cells testing method to examine malignancies from pleural effusion specimens. To obtain high-quality  ETC libraries, they selected 5 representative patient samples each consisting of either a single cell or a small cell cluster. To generate Next-Generation Sequencing libraries, cell lysates were used as template with the CleanPlex OncoZoom Cancer Hotspot NGS Panel. Data Analysis and ETC Pool Variant Analysis was also performed. They retrieved high-quality sequencing results with great coverage uniformity. In this study, the authors developed a novel ETC-testing assay that detected epithelial malignancies in pleural effusions with 89.5% sensitivity and 100% specificity. Molecular profiling of ETCs showed promising concordance with their respective clinical molecular findings.

Functional CRISPR dissection

Functional CRISPR dissection of gene networks controlling human regulatory T cell identity

Prof. Alexander Marson from University of California, San Francisco (UCSF), CA, USA in collaboration with researchers from University of California, Berkeley, CA, USA, Technische Universität München (TUM), Munich, Germany and multiple renowned Cancer Immunotherapy institutes in San Francisco published findings in Nature Immunology showing CRISPR–Cas9 ribonucleoprotein (RNP) technology allows dissection of complex gene modules in primary human Treg cells through targeted gene perturbation studies. Using our CleanPlex custom panels, researchers were able to perform CRISPR editing efficiency check and show pooled Cas9 RNP screens link indels with phenotypic changes in human Treg cells. The overall study resulted in functional network maps which may help to guide future development of drug targets and design of Treg cell– based immunotherapies.

Somatic Mutations And T-Cell Clonality

Somatic Mutations And T-Cell Clonality In Patients With Immunodeficiency

Dr. Satu Mustjoki and fellow researchers from University of Helsinki, Finland, in collaboration with the University Hospital and Computer Science Department of Aalto University School of Science, report an increase in somatic mutations in CD4+ and CD8+ T cells of patients with immunodeficiency. The team used a custom CleanPlex Panel to validate the low VAF somatic mutations to gain higher confidence in their findings.

Molecular assessment of pretransplant chemotherapy

Molecular assessment of pretransplant chemotherapy in the treatment of leukemia

Prof. Elliot Stieglitz‘s Lab at the UCSF Benioff Children’s Hospital developed a NGS assay powered by Paragon Genomics’ CleanPlex technology to measure the molecular burden of juvenile myelomonocytic leukemia (JMML). The researchers demonstrated that molecular testing can be helpful to distinguish between responders and nonresponders and should become an integral part of clinical care.

Omicron Sub-Lineage BA.5 and Recombinant XBB Evasion

Genomic malaria surveillance of antenatal care users detects reduced transmission following elimination interventions in Mozambique

The research outlines how genomic surveillance, notably using the Paragon Genomics CleanPlex Malaria NGS Panel, at antenatal care visits in Mozambique demonstrates a decline in malaria transmission following elimination efforts. It highlights the consistent genetic diversity and drug resistance between malaria parasites in pregnant women and children, noting a significant genetic diversity reduction in targeted areas, indicative of reduced parasite populations. This approach underscores the potential of advanced genomic tools in enhancing malaria control and eradication strategies.

Omicron Sub-Lineage BA.5 and Recombinant XBB Evasion

Omicron Sub-Lineage BA.5 and Recombinant XBB Evasion from Antibody Neutralisation in BNT162b2 Vaccine Recipients

Presently, the XBB recombinant variant, a hybrid of BA.2.10 and BA.2.75, which was first detected in August 2022, has given rise to apprehension due to its theoretically augmented infectivity and immune escape ability. In this study, authors tested the ability of this recombinant to evade vaccine-induced antibody neutralization compared to the ancestral lineage (B.1) and another co-circulating variant (B.1.1.529 BA.5) and were able to confirm that both BA.5 and XBB are significantly more immune-evasive, and to demonstrate that a specific vaccine (BNT162b2, BioNTech, Pfizer) only achieves a partial cross-neutralization of novel variants. The authors used Paragon’s CleanPlex SARS-CoV-2 FLEX NGS Kit for lineage identification of the clinical specimens, thereby showcasing the robustness of the FLEX degenerate primers for current SARS-CoV-2 variant identification capabilities.

COVID-19 Infection and Transmission Includes Complex Sequence Diversity

Comparison of SNVs between Immunocompetent (IM+) and Immunocompromised (IM-)

COVID-19 Infection and Transmission Includes Complex Sequence Diversity

Dr Peter Zimmerman and colleagues at Case Western Reserve University were interested in characterizing the sequence diversity of the SARS-CoV-2 beyond the commonly reported majority consensus sequence in attempts to make new variant surges more easily detected and further understand and characterize infectious complexity. In this study, they used CleanPlex SARS-CoV-2 (panels 918010/918011) for whole genome sequencing of SARS-CoV-2 followed by variant calling on 254 clinical samples from COVID-19 patients to detect nucleotide changes outside of the consensus sequence region. The authors were able to detect a few mixed infection cases that occurred before the variant was publicly reported in the region, which may shed light on the usefulness for tracking SARS-CoV-2 beyond the consensus sequence for proper detection of new viral variants that may emerge during the pandemic.

Infectious Disease

Sequencing SARS-CoV-2 from antigen tests

Since the start of the pandemic, real time RT-PCR diagnostic testing from upper respiratory specimens, such as nasopharyngeal (NP) swabs, has been the standard. In early 2021, many clinicians transitioned to antigen-based SARS-CoV-2 detection tests, which use anterior nasal swabs for SARS-CoV-2 antigen detection. Despite this shift in testing methods, the need for whole-genome sequence surveillance remains. They researchers developed a workflow for whole-genome sequencing with antigen test-derived swabs as an input and proved that used swabs from a common Ag Card test can be re-extracted and is feasible for sequencing and yields similar results from RT-PCR-based assays utilizing a swab in viral transport media.

Infectious Disease

First identification of the new SARS-CoV-2 Omicron variant (B.1.1.529) in Italy

The first case of SARS-CoV-2 B.1.1.529 (omicron) variant in Italy and the second case across Europe was identified by the Clinical Laboratory of Microbiology, Virology and Bioemergencies of L.Sacco University Hospital with the CleanPlex SARS-CoV-2 Panel kit from Paragon Genomics. With different waves of viral mutation and propagation, a strong sequencing front to monitor and survey the virus landscape is more essential than ever in this public health crisis. In Italy, L.Sacco University Hospital was able to sequence and assign definitive lineage of a traveler’s viral sample due to the presence of amino acid substitution S371L specific for the new lineage B.1.1.529 (omicron) with the CleanPlex SARS-CoV-2 Panel. The lineage was assigned by the I-Co-Gen platform, present on GISAID with code EPI_ISL_6777160, and confirmed by the Pangolin COVID-19 Lineage Assigner. The result was shared immediately with the National Institute of Health in Italy and informed health authorities to take public health measures and restrict travel policies accordingly.

External quality assessment of SARS-CoV-2-sequencing

External quality assessment of SARS-CoV-2-sequencing: An ESGMD-SSM (ESCMID Study Group for Genomic and Molecular Diagnostics - Swiss Society for Microbiology) pilot trial across 15 European laboratories

This first pilot study on external quality assessment of the SARS-CoV-2 whole genome sequencing was initiated by the ESGMD-SSM Study Group in Europe. Their aim was to build a framework between laboratories to improve COVID-19 surveillance sequencing. Ten samples with varying viral loads (Ct values = 19 to 28) were sent out to 15 different clinical laboratories who had free choice of library preparation kits, sequencing methods and bioinformatic analyses. The key aspects on which the individual centers were compared on were identification of 1) SNPs and indels, 2) Pango lineages, and 3) clusters between samples. The participating laboratories used a wide array of amplicon based library preparation methods including Illumina’s COVIDSeq test, ARTIC v3 workflow on both the Illumina and Oxford Nanopore sequencing technology and Paragon Genomics Inc.’s CleanPlex SARS-CoV-2 targeted amplicon technology. Most labs were able to generate whole genomes for all samples even with varying sequencing depth. There was a very good consensus regarding the majority of reporting criteria, but there were a few discrepancies in lineage and cluster assignment and variant calling. However, the CleanPlex SARS-CoV-2 amplicon sequencing technology (used in center 4), outperformed in almost all areas. CleanPlex’s results had the highest variant calling score in addition to the best accuracy, with no false positives (wrong) / false negative (missing) calls across all 10 samples (not even achieved by Illumina COVIDSeq, even with very deep sequencing).

SARS-CoV-2 samples

A deletion in the N gene may cause diagnostic escape in SARS-CoV-2 samples

Prof. Sambri and his team at The Great Romagna Hub laboratory in Italy investigated a case study where routine diagnostic testing for COVID-19 showed discrepant results. After performing amplicon based Next Generation Sequencing with the CleanPlex SARS-CoV-2 kit to decode the viral genome, researchers were able to identify a consistent deletion in the region of the N gene as causal for diagnostic failure. As mutations in SARS-CoV-2 can confer ability to evade detection by RT-PCR, it is essential to continue surveying viral evolution and monitoring diagnostic accuracy via sequencing-based confirmation to mitigate false-negative PCR-based tests.

Paragon Genomics is proud to offer the CleanPlex SARS-CoV-2 FLEX Panel and Emerging Variants Panel Add-on specifically designed to contain additional components for robust and confident variant calling even when the virus mutates over time.

SARS-CoV-2 variant detection

SARS-CoV-2 variant detection at a university dormitory using wastewater genomic tools

Prof. Oh from the University of Nevada along with his colleagues from the University of Arizona performed a WGS study to detect SARS-CoV-2 variants in wastewater collected at a university dormitory. Total RNA from wastewater was used to generate viral libraries using the CleanPlex SARS-CoV-2 FLEX Panel. Analysis of the sequencing results identified a mixture of two viral signatures that included clade 20C, with signature 20C mutations C1059T and G25563T, and another emerging viral strain corresponding to a 20A+20268G subclade. Compared to hybrid capture and other amplicon-based technologies, the lab was able to show libraries prepared using the CleanPlex SARS-CoV-2 FLEX Panel along with their genomic tools had the specificity and sensitivity to sequence single viral genomes. The investigators propose the implementation of cost-effective WGS, which enables public health authorities to definitively identify viral strains and manage local outbreaks compared to qPCR and digital PCR strategies which can be cost prohibitive.

Assessment of SARS-CoV-2 genome sequencing

Assessment of SARS-CoV-2 genome sequencing: quality criteria and low frequency variants

Prof. Claire Bertelli and her team at the Lausanne University Hospital performed a study to assess the sequencing quality criteria, especially for low frequency variants of the SARS-CoV-2 genome. The lab retrospectively investigated 647 SARS-CoV-2 genomes obtained over 10 tiled amplicons sequencing runs and identified eleven metrics associated with sequencing quality useful to easily implement quality enhancement measures. These amplicon libraries were constructed using the CleanPlex SARS-CoV-2 panel. Low frequency variants can result from PCR amplification errors, sample cross contaminations or presence of distinct SARS-CoV-2 genomes in the sample sequenced. To ensure the accuracy of SARS-CoV-2 genome sequences, it is essential to identify and distinguish PCR errors as well as potential sample cross-contaminations. Therefore, the team strongly recommends evaluating the proportion of low frequency variants, their prevalence in other SARS-CoV-2 samples from the same sequencing run, as well as their prevalence in all SARS-CoV-2 sequenced to date as a technical control before data submission to public health agencies and public databases. Their aim to provide simple quality control criteria for SARS-CoV-2 sequencing to prevent erroneous interpretation of low quality or contaminated data was accomplished.

First reported cases of SARS-CoV-2 sub-lineage B.1.617.2

First reported cases of SARS-CoV-2 sub-lineage B.1.617.2 in Brazil: an outbreak in a ship and alert for spread

Prof. Luana Silva Soares and colleagues from the Department of Virology, Para state, Brazil reported the first instance of a SARS-CoV-2 B.1.617.2 (VoC) outbreak in an Asiatic origin trade ship which traveled from Malaysia and docked in Brazil. Nasopharyngeal swabs from 24 crew members were collected. The laboratory diagnosis was performed using RT-qPCR. Positive samples were used to perform Next Generation Sequencing using CleanPlex® SARS-CoV-2 Research and Surveillance Panel kits. SARS-CoV-2 genomes were obtained and classified as a B.1.617 lineage, confirmed by Pangolin lineage classification. Genetically, the B.1.617 lineage has a particular signature in the Spike protein, characterized by six marker mutations. In addition to those marker mutations, 21 other changes in the Spike protein were also observed in the NGS data. In conclusion, the lab reports the early detection of the SARS-CoV-2 lineage B.1.617 in Brazil. Since there are many factors still unclear about this VoC B.1.617.2, this single outbreak reinforces the necessity of continuous monitoring of travelers to follow the real-time spread of this new SARS-CoV-2 VoC, that could impact public health as well as immunization strategies.

Use of whole genome sequencing

Genetic variant profiles of the sequenced SARS-CoV-2 relative to the Wuhan-Hu-1 reference genome.

Use of whole genome sequencing to investigate a cluster of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infections in emergency department personnel

Prof. Zimmerman from Case Western University and Prof. Donskey from the Cleveland VA Medical Centre performed a joint study to investigate a cluster of SARS-CoV-2 infections in 6 symptomatic emergency department personnel and 2 control COVID-19 patients. They used the CleanPlex SARS-CoV-2 Panel to perform viral whole genome sequencing to conduct this contact tracing investigation. Their results demonstrated that the suspected 6-person outbreak included 2 distinct transmission clusters and 1 unrelated infection. Their results suggest that SARS-CoV-2 variants initially acquired in the community were subsequently spread among hospital personnel. Hence, they concluded that such SARS-CoV-2 sequencing studies are needed to provide more definitive evidence regarding personnel as a source of transmission.

Genomic Epidemiology of SARS-CoV-2 Infection

Genomic Epidemiology of SARS-CoV-2 Infection During the Initial Pandemic Wave and Association With Disease Severity

Prof. Rubin and Prof. Li from Case Western University along with their colleagues from Cleveland Clinic Ohio performed a cross-sectional study on 302 patients to examine the association of identified SARS-CoV-2 variants, virus clades, and clade groups with disease severity and patient outcomes. Whole genome sequencing of the virus was performed using the CleanPlex SARS-CoV-2 Panel followed by variant calling. Understanding of SARS-CoV-2 variants that alter disease outcomes are important for clinical risk stratification and provide important clues to the complex virus-host relationship. This study demonstrates a dynamic shift in SARS-CoV-2 clade diversity occurring very early in the pandemic.  These findings suggest that SARS-CoV-2 clade assignment is an important factor that may aid in estimating patient outcomes.

Genome Sequencing and Phylogenetic Analysis of SARS‑CoV‑2 strains

Whole Genome Sequencing and Phylogenetic Analysis of SARS‑CoV‑2 strains in Turkey

Prof. Hakan Akca from Pamukkale University, Turkey, performed whole genome sequencing on 15 COVID-19 positive patients using CleanPlex SARS-CoV-2 Panel . They identified 32 missense, 21 synonymous, and 4 non-coding allele mutations. Out of the missense mutations identified, 11 were rare missense mutations in the virus compared to the reference genome. Phylogenetic analysis revealed that most of the isolates were similar to European sequences. The phylogenetic tree constructed with all the complete SARS-CoV-2 genomes of Turkey showed that the viruses were spread nearly homogenous on eastern and western sides of Turkey.

Evidence of SARS-CoV-2 reinfection within the same clade

Evidence of SARS-CoV-2 reinfection within the same clade in Ecuador: A case study

Normally, reported SARS-CoV-2 reinfection cases are mainly seen in strains belonging to different clades however Prof. Zurita from Ecuador identified a case of reinfection within the same clade. Both, the infection and reinfection strains, were assigned as Nextstrain 20B, Pangolin lineage B.1.1 and GISAID clade O. These results were obtained by whole genome sequencing of the SARS-CoV-2 virus using the CleanPlex SARS-CoV-2 Panel. These results showed evidence that SARS-CoV-2 reinfection can occur within the same clade and previous infection to the virus cannot render complete immunity in all cases.

SARS-CoV-2 Reinfection in a Healthcare Worker

SARS-CoV-2 Reinfection in a Healthcare Worker Despite the Presence of Detectable Neutralizing Antibodies

Prof. Lütgehetmann from University Medical Center Hamburg-Eppendorf along with his colleagues from German Center for Infection Research performed a study to investigate the SARSCoV2 reinfection despite presence of detectable neutralizing antibodies in a female healthcare worker. Next generation sequencing (NGS) of the viral genome from the pharyngeal swab was performed using the CleanPlex SARS-CoV-2 Panel from the first and second episode of infection and were named #HH-24.I and HH-24.II, respectively. The NGS data revealed that the viral sequences from the initial virus variant in March (HH-24.I) and the variant in December (HH 24.II) belonged to pangoline lineages B.3 and B.1.177, respectively. In total, both sequences differed in 21 positions including two typical variations in spike proteins A222V and D614G. The team concluded that a better understanding about reinfection events may help to identify serological correlates of immunity.

Utility of viral whole genome sequencing

Utility of viral whole genome sequencing for institutional infection surveillance during the SARS-CoV-2 pandemic

Prof. Dien Bard and Prof. Gai from Children’s Hospital Los Angeles (CHLA) along with their colleagues from the Keck School of Medicine, USC performed whole genome sequencing (WGS) of 70 SARS-CoV-2 positive individuals using the CleanPlex SARS-CoV-2 NGS panel to evaluate institutional infection surveillance within a 9-month period. The researchers identified 25 potential clusters that warranted further exploration by WGS. Of the 25 suspected clusters analyzed, conclusive results were available in 23 cases from which they confirmed some relatedness in 14 clusters suspected by the contact tracing team including an outbreak within a unit. Importantly, WGS allowed them to rule out 9 highly suspicious clusters within the same units, demonstrating that these were not healthcare-associated infections. WGS analysis of SARS-CoV-2 isolates allowed the research team to monitor disease spread, outbreak dynamics, and infection hot spots within their institution and provided the capability to rule-out suspected clusters and confirm unrelated sources of infection. The team concluded that WGS analysis during the COVID-19 pandemic can be highly effective in a clinical setting as a complement to contact tracing efforts and will become increasingly important in identifying outbreaks.

Recommendations for accurate genotyping

Recommendations for accurate genotyping of SARS-CoV-2 using amplicon-based sequencing of clinical samples

SOPHiA Genetics and researchers from 6 different institutes sequenced 200 clinical samples with Paragon Genomics’ CleanPlex SARS-CoV-2 Panel kit to generate what the authors claim as “much-needed recommendations” and guidelines for sequencing and genotyping of SARS-CoV-2 samples. They set criteria for accurate variant detection down to 10%, which enables sample tracing based on geographical origin and time of sampling. Additionally, the researchers identified dissemination patterns of the viral variants 20A.EU1 and 20A.EU2, which were linked to summer travel in 2020 across Europe. The results indicate high specificity with “virtual absence of sequencing reads mapping to the human transcriptome” and high uniformity that are trademarks of Paragon Genomics’ CleanPlex technology. Although more investigation is needed in the global fight against COVID-19, Paragon Genomics is proud to be helping the research community in its quest for better understanding of the SARS-CoV-2 genome.

Detection of SARS-CoV-2 lineage P.1

Detection of SARS-CoV-2 lineage P.1 in patients from a region with exponentially increasing hospitalization rates in February 2021, Rio Grande do Sul, Southern Brazil

Prof. Luis Barth and his colleagues from Federal University of Rio Grande do Sul and Hospital de Clínicas de Porto Alegre performed a study to look at the association of the emergence of the SARS-CoV-2 P.1 lineage and the rapid growth in hospitalization in the northern region of Brazil.  Whole-genome sequencing of 68 patient specimens was performed using the CleanPlex SARS-CoV-2 panel and the data revealed that the previously undetected P.1 lineage was now detected and accounted for 88.9% of specimens collected from patients at a referral COVID-19 hospital. These findings raise concerns regarding a possible association between the lineage P.1 and rapid growth in cases and hospitalizations in the Rio Grande do Sul area.

Emerging variants of concern in SARS-CoV-2 membrane protein

Emerging variants of concern in SARS-CoV-2 membrane protein: a highly conserved target with potential pathological and therapeutic implications

Prof. Biegel and Prof. Gai from Children’s Hospital Los Angeles (CHLA) along with their colleagues from the Keck School of Medicine, USC evaluated whole genome sequencing data from a cohort of 143,609 USA SARS-CoV-2 viral genomes to study the recent spike in frequency of the membrane protein (M) gene mutations in the SARS-CoV-2 genome. This cohort included 2,900 patients from CHLA whose whole genome data was generated using the CleanPlex SARS-CoV-2 NGS panel. The group reported a new Variant Of Concern with a signature mutation in the M gene, an otherwise overlooked but significant site of increasing numbers of mutations. In silico analysis revealed that the M protein structure is similar to that of the glucose transporter based upon which the M protein is thought to be involved in rapid viral proliferation, replication, and immune evasion. In the last few months, the incidence of some missense M gene mutations have increased over 100 fold and continue to increase. Hence, the researchers suggest that M gene mutations should be included in ongoing genomic surveillance efforts and warrants further evaluation.

spread of SARS-CoV-2 VOC202012/01 B.1.1.7 variant

A straightforward molecular strategy to retrospectively investigate the spread of SARS-CoV-2 VOC202012/01 B.1.1.7 variant

Prof. Uzzau from University of Sassari along with his colleagues from Sassari University Hospital in Italy performed a retrospective study to investigate the spread of the SARSCoV2 Variant of Concern (VOC) 202012/01 B.1.1.7 in North Italy. They performed whole genome sequencing using the CleanPlex SARS-CoV-2 NGS Panel to confirm inconclusive diagnostic RT-PCR results. According to the Pangolin application, the analyses of this NGS data enabled the researchers to assign these viral genomes to SARS-CoV-2 lineages, confirming the presence of the B.1.1.7 variant. The CleanPlex SARS-CoV-2 NGS panel was able to ID the characteristic mutations along the whole SARS-CoV-2 viral genome including the mutations in the S gene encoding for Spike protein. Such variants represent a serious threat worldwide, thus conclusive and rapid methods are required for their identification.

Persistent SARS-CoV-2 infection and increasing viral variants

Persistent SARS-CoV-2 infection and increasing viral variants in children and young adults with impaired humoral immunity

Prof. Dien Bard and Prof. Gai from Children’s Hospital Los Angeles (CHLA) along with their colleagues from Stanford and Johns Hopkins performed a study in three patients with impaired humoral immunity who were persistently positive for SARS-CoV-2 infection. Whole-genome sequencing was performed using the CleanPlex SARS-CoV-2 Research and Surveillance NGS Panel and serological studies were performed to measure viral evolution and evidence of immune escape. Their work demonstrates that immunocompromised pediatric and young adult patients are susceptible to prolonged viral infections with continued virus shedding and mutation accumulation some with the potential to escape antibody neutralization. Their results highlight the need to reassess infection control precautions in the management and care of immunocompromised patients. Routine surveillance of mutations and evaluation of their potential impact on viral transmission and immune escape should be considered.

Genomic epidemiology of SARS-CoV-2

Genomic epidemiology of SARS-CoV-2 reveals multiple lineages and early spread of SARS-CoV-2 infections in Lombardy, Italy

Prof. Fausto Baldanti from Univeristy of Pavia, Italy and Prof. Carlo Federico Perno from Children’s Hospital, IRCCS, Rome, Italy along with their colleagues from University of Milan, Italy and ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy performed a genomic epidemiology study of the SARS-CoV-2 genomes in Lombardy, Italy. In this study, they used an integrated approach comprising of both epidemiological and viral genetic data to reconstruct the pattern of the SARS-CoV-2 spread in this region. Whole-genome sequencing was performed using the CleanPlex SARS-CoV-2 Research and Surveillance NGS Panel for 346 SARS-CoV-2 strains obtained from individuals from various geographical areas in a time span of 2 months. In conclusion, this study contributed to the identification and circulation pattern of seven SARS-CoV-2 lineages in an area highly affected by COVID-19. In addition, they demonstrated the presence of local transmission clusters within three of those lineages, revealing that sustained community transmission was underway before the first COVID-19 case had been detected in Lombardy.

Early pandemic molecular diversity of SARS-CoV-2

Early pandemic molecular diversity of SARS-CoV-2 in children

Prof. Paul Planet from Children’s Hospital of Philadelphia (CHOP) and Prof. Dien Bard and Prof. Gai from Children’s Hospital Los Angeles (CHLA) along with their colleagues from USC and UPenn performed a study in a pediatric population to track the molecular epidemiology of the SARS-CoV-2 virus locally in Philadelphia. They used the CleanPlex SARS-CoV-2 Research and Surveillance NGS Panel to perform whole genome sequencing followed by novel genotyping tools to quantifying the viral diversity on 169 SARS-CoV-2 genomes (83 genomes <21 years old) collected over three months. They show that the early pandemic and peak in Philadelphia were characterized by multiple, diverse, circulating viral variants, especially amongst children. Their analysis uncovered 13 major lineages that changed in relative abundance as cases peaked in mid-April. They conclude that no clear differences in clinical presentation were associated with the different virus lineages.

Detection of the new SARS-CoV-2 variant B.1.526

Detection of the new SARS-CoV-2 variant B.1.526 with the Spike E484K mutation in South America

Prof. Derly Andrade Molina from Espiritu Santo University and Prof. Ricardo Soto Rifo from University of Chile along with their colleagues performed an epidemiological surveillance and reported two sequences in South America of the new SARS-CoV-2 variant, B.1.526, harboring the immune escape-associated mutation E484K. These viral sequences of the new variant were obtained from two individuals with a negative RT-PCR test but were analyzed further by whole genome sequencing using the CleanPlex ® SARS-CoV-2 FLEX Panel.  From all the mutations identified in this new variant, mutation E484K is located in the receptor binding domain of the spike protein hence being considered a variant of concern. Such variants can be transmitted faster and could be implicated in increased mortality and decreased vaccine efficiency. Therefore, the researchers conclude that genomic and immune surveillance are critical to determining the impact of this new variant in SARS-CoV-2 transmission and immunity dynamics.

Infectious Disease

Whole-genome Sequencing of SARS-CoV-2: Using Phylogeny & Structural Modeling to Contextualize Local Viral Evolution

Researchers at 59th Medical Wing, Clinical Investigations & Research Support Laboratory presented a pipeline for molecular epidemiological surveillance enabling public health officials to track viral evolution and outbreaks. The entire workflow including RNA extraction, library preparation with Paragon Genomics’ CleanPlex SARS-CoV-2 Panel, and data visualization plus analysis can be completed in less than one week. The research team concluded that “in the event that actionable sequencing data is required, tiling library prep is the most efficient and effective method”, in comparison to shotgun and hybrid capture methods.

High Prevalence of SARS-CoV-2 Genetic Variation and D614G Mutation

High Prevalence of SARS-CoV-2 Genetic Variation and D614G Mutation in Pediatric Patients with COVID-19

Prof. Jennifer Dien Bard and Prof. Xiaowu Gai along with their colleagues from Children’s Hospital Los Angeles and Keck School of Medicine at USC,  performed a study in pediatric patients infected with COVID-19 to study the genetic diversity of the SARS-CoV-2 viral genome. Whole genome sequencing was performed on extracted viral RNA from respiratory specimens collected on all SARS-CoV-2 positive children (n=141) using Paragon Genomics CleanPlex SARS-CoV-2 Research and Surveillance NGS Panel. They analyzed the relationships between viral genetic variants and clinical characteristics in children. Genomic evaluation demonstrated greater than expected genetic diversity, presence of the D614G mutation in the viral spike protein, increased mutation rate, and evidence of multiple introductions of SARSCoV-2 into Southern California. Their findings suggest a possible association of phylogenetic clade 20C with severe disease, but small sample size precludes a definitive conclusion. The researchers suggest a further multi-institutional genomic evaluation is needed and can have implications on infection control practices.

PCORI Health Care Horizon Scanning System

PCORI Health Care Horizon Scanning System: Horizon Scanning COVID-19 Supplemental High Impact Report

The PCORI Health Care Horizon Scanning System has recently made a notable mention of Paragon Genomics to the likes of companies such as Illumina and Helix to be instrumental in developing several NGS assays for COVID-19 testing. The Horizon Scanning System identifies technology and systems innovations that could disrupt or cause significant shifts in health care. The Horizon scanning system can identify new (and new uses of existing) lab tests and procedures, public health and health promotion activities, and therapeutic interventions. They have issued a high impact report this September 2020 reporting several companies like Illumina, Paragon Genomics, Helix and others that have developed several NGS assays that can employ deep sequencing and computational methods to detect nucleic acids of the coronavirus. Such tests can amplify and detect sequences from the whole viral genome or several genomic regions. In their words ”NGS assays purportedly offer high throughput, enabling 2000 to 3000 samples to be processed in about 12 hours, with accuracy comparable to that of standard PCR tests and these assays might also be used in epidemiology studies to track the spread of coronavirus or to screen individuals who are planning to return to work or school.”

Within-host diversity of SARS-CoV-2 in COVID-19 patients

Within-host diversity of SARS-CoV-2 in COVID-19 patients with variable disease severities

Prof. Hadi M. Yassine from Qatar University in Doha, Qatar in collaboration with other researchers investigated the within-host SARS-CoV-2 virus diversity of 19 and 27 COVID-19 patients with mild and severe clinical manifestations respectively. Using our CleanPlex® SARS-CoV-2 Panel kit they performed targeted virus genome sequencing and reported patients with severe symptoms exhibited a significantly higher number of variants in coding and non-coding regions compared to mild cases. Their analysis also revealed higher prevalence of certain variants among severe cases only. Most importantly, severe cases exhibited significantly higher within-host diversity compared to mild cases. These observations helped them conclude that within-host diversity of the virus might play a role in the development of severe disease outcomes in COVID-19 patients.

Characterization of local SARS-CoV-2

Characterization of local SARS-CoV-2 isolates and pathogenicity in IFNAR−/- mice

Prof. Aykut Özkul from Ankara University in Turkey performed a study to isolate SARS-CoV-2 viruses circulating in Anatolia, and to investigate virus propagation in frequently-used cells and experimental animals. Using our CleanPlex® SARS-CoV-2 panel for their amplicon-based next generation sequencing, they identified two local SARS-CoV-2 virus isolates, and investigated in vitro growth dynamics in frequently-used Vero E6 cells and identified IFNAR−/− mice as a potential animal model for SARS-CoV-2 experiments.

Pediatric COVID-19

Pediatric COVID-19 in Southern California: clinical features and viral genetic diversity

Prof. Xiaowu Gai and Prof. Jennifer Dien Bard from Children’s Hospital Los Angeles (CHLA) recently published a paper exploring clinical features and SARS-CoV-2 genetic variation in children presenting with COVID-19. They observed diverse clinical presentations and identified association between disease severity, viral load and age. By using CleanPlex SARS-CoV-2 Research and Surveillance NGS Panel, they were able to conduct highly sensitive and full-genome interrogation of the SARS-CoV-2 virus using amplicon sequencing on Illumina platforms.

microhaplotypes from the Plasmodium falciparum heterozygome

Sensitive, highly multiplexed sequencing of microhaplotypes from the Plasmodium falciparum heterozygome

Prof. Bryan Greenhouse, Dr. Sofonias Tessema and fellow researchers from Chan Zuckerberg Biohub, University of San Francisco, USA in collaboration with researchers from University of Massachusetts, Brown University, Clinton Health Access Initiative, and Centro de Investigação em Saúde de Manhiça (CISM) of Mozambique demonstrated that targeted NGS sequencing with a custom CleanPlex Panel is a flexible, low cost, “promising tool for studying the transmission dynamics of  P. falciparum” infections (Malaria), without the need for WGA, describing that in fact, their CleanPlex approach “outperformed whole genome sequences obtained from 50 times more total reads”. They further go on to note that their custom CleanPlex Panel “demonstrated high specificity regardless of the proportions of strains in the mixture (true positive rate = 99.8)… [and] sensitivity of the method was high across a wide range of parasite densities.”

The origin of SARS-CoV-2

The origin of SARS-CoV-2 in Istanbul: Sequencing findings from the epicenter of the pandemic in Turkey

Prof. Dinler-Doganay’s Lab at Istanbul Technical University, Prof. Doganay and his colleagues at University of Health Sciences, Istanbul, Turkey and Dr. Ilker Karacan from Science and Advanced Technology Research Center, Istanbul, Turkey reported the SARS-CoV-2 viral genomes circulating in Istanbul for the first time. By using Paragon Genomics’ CleanPlex SARS-CoV-2 Research and Surveillance Panel, amplicon-based next-generation sequencing approach was successfully applied to generate near-complete genomes with an average depth of 2616. All three viral genomes carried the D614G variant (G clade according to GISAID classification) with implications for the origin of a spread.

Highly sensitive and full-genome interrogation of SARS-CoV-2

Highly sensitive and full-genome interrogation of SARS-CoV-2 using multiplexed PCR enrichment followed by next-generation sequencing

Prof. Xiaowu Gai and Prof. Jennifer Dien Bard from Children’s Hospital Los Angeles (CHLA), Paragon Genomics R&D teams led by Dr. Zhitong Liu, Prof. Alexander Urban from Stanford University and scientists from MGI / BGI-ShenZhen collaborated on sequencing COVID-19 patient samples using Paragon Genomics’s CleanPlex SARS-CoV-2 Panel for highly sensitive and full-genome interrogation of the SARS-CoV-2 virus using multiplexed PCR enrichment followed by next-generation sequencing.

NOTCH3 Variants in Patients with Suspected CADASIL

NOTCH3 Variants in Patients with Suspected CADASIL

Dr. Gorukmez from the Department of Medical Genetics and Neurology in Turkey has published findings investigating genetic variants of NOTCH3 in individuals with suspected cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), which is a rare hereditary form of cerebral small vessel disease. The researchers utilized Paragon Genomics’s CleanPlex technology to generate a custom targeted sequencing panel for analyzing patient samples isolated from blood and accurately identifying pathogenic variants in the NOTCH3 gene. By leveraging the Sophia DDM platform, the team successfully detected 30 different disease-causing variants, including 17 novel variants, in the patient group. These findings contribute valuable insights into the diagnosis and management of CADASIL, highlighting the significance of understanding the genetic basis of CADASIL and its potential impact on personalized medicine approaches.

assessment of prevalence of Type 1 CFI rare variants

An assessment of prevalence of Type 1 CFI rare variants in European AMD, and why lack of broader genetic data hinders development of new treatments and healthcare access

Age related macular degeneration (AAMD) risk is associated with CFI (human complement factor I), but it remains unclear how variant prevalences might differ by ethnicity. To evaluate the prevalence of Type 1 CFI rare variant genotypes, targeted sequencing using Paragon’s CleanPlex technology was performed over the CFI coding region plus 50bp on either side of the intron/exon boundaries to determine VAF. Different ethnicities displayed markedly varying degrees of CFI variant prevalence, which further reinforces the need to generate more multi-ethnic AAMD datasets to better understand the impact of CFI genetic diversity on disease risk, and contribute to the emergence of novel tailored treatments.

Modulation of autoimmune diabetes

Modulation of autoimmune diabetes by N-ethyl-N-nitrosourea- induced mutations in non-obese diabetic mice

Modulation of autoimmune diabetes by ENU-induced mutations in Non-Obese Diabetic mice

Dr. Bruce Beutler and colleagues from UT Southwestern Medical Center in collaboration with Dr. Lucienne Chatenoud from Université de Paris were interested in clarifying specific genes that could be linked to type 1 diabetes. Using a plethora of mouse models, they applied custom panels from Paragon Genomics for loci detection and Ion Torrent sequencing on over 800 mice from 14 pedigrees bearing ~600 coding/splicing changes and identified several mutations that either accelerated, delayed, or suppressed type 1 diabetes development in their models, which may provide new insights to understanding human susceptibility to type 1 diabetes.

The role of genetic mutations in intrahepatic cholestasis of pregnancy

The role of genetic mutations in intrahepatic cholestasis of pregnancy

Dr. Gültekin Adanaş Aydın, Dr. Gülten Özgen, and Dr. Orhan Görükmez from Bursa Yuksek Ihtisas Training and Research Hospital, Bursa, Turkey published a paper about the role of genetic mutations in intrahepatic cholestasis of pregnancy using a CleanPlex custom panel.

Parkin-mediated mitophagy and autophagy flux disruption

Parkin-mediated mitophagy and autophagy flux disruption in cellular models of MERRF syndrome

Prof. José A.Sánchez-Alcázar and fellow researchers from University of Pablo de Olavide, Spain collaborated with researchers from Department of Neurology, Uniklinikum C. G. Carus, Dresden, Germany and Instituto de Salud Carlos III, Spain and used CleanPlex Mitochondrial Disease Panel to study parkin-mediated mitophagy and autophagy flux disruption in cellular models of MERRF syndrome.

Building phylogenomic data sets

Building phylogenomic data sets using highly multiplexed amplicon sequencing

Dr. Scott Geib and fellow researchers at the USDA-Agricultural Research Service developed new approach for building phylogenomic data sets using highly multiplexed amplicon sequencing powered by Paragon Genomics’ CleanPlex technology. The work provided unparalleled resolution of phylogenetic relationships in fruit flies.

About Paragon Genomics

Our mission is to provide high-quality target enrichment solutions to the genomics community to advance precision medicine and research.

At Paragon Genomics, we are a passionate group dedicated to providing cutting-edge technologies and solutions for the global genomic research and application community. Our goal is to move precision medicine forward. The team is composed of industry veterans and academic experts who previously worked with well-known industry-leading companies and institutions such as ThermoFisher Scientific, Life Technologies, PerkinElmer, Beckman Coulter, Affymetrix, Novartis, Applied Biosystems, Siemens Healthcare, Stanford and Harvard.

Paragon Genomics’ leadership team proudly graduated from the California Life Sciences Institute’s (CLSI) Spring 2016 FAST Advisory Program. We were also honored to be accepted into the renowned StartX Fall 2016 Accelerator Program.



Dr. Bryan Greenhouse

Bryan Greenhouse, MD Professor, Medicine School of Medicine, UCSF

paragon genomics

The Old Fight is New: Tackling Malaria with Next-Generation Sequencing

The modular targeted panel from UCSF empowers researchers across the world to take a deep-dive into the genome of P. falciparum

Malaria, a parasitic disease transmitted primarily through the bite of infected mosquitoes, poses a significant public health challenge. The most commonly observed symptoms in patients include fever, chills, and flu-like illness. However, if left untreated, the disease can lead to severe complications, debilitation, and death.

Malaria is predominantly prevalent in tropical and subtropical regions, putting nearly half of the global population at risk. In regions like Africa, it stands as the second leading cause of illness and mortality. Recent estimates indicate a staggering 241 million cases of malaria worldwide, resulting in approximately 627,000 annual fatalities.1 In recent events, the CDC issued a health advisory to alert the public (in June 2023) of the first known locally acquired cases of malaria in the United States since 2003.2 But the impact of malaria extends beyond individual health – it exerts a significant economic burden on individuals, families, communities, and nations. The costs associated with malaria treatment and eradication efforts are substantial, encompassing both direct healthcare expenses and indirect costs. Conservative estimates place the direct costs at a minimum of $12 billion per year, with considerable implications for economic growth and development.

Over the past six years, the field of malaria research has greatly benefitted from advancements in sequencing-based technology. This groundbreaking approach has opened new frontiers for exploration, and one prominent figure leading the charge is Dr. Bryan Greenhouse and his team at the University of California, San Francisco (UCSF). Fueled by the generous support of the Bill and Melinda Gates Foundation and the National Institute of Health, their lab has explored questions related to population genetics, transmission dynamics, and drug resistance surveillance. As malaria continues to evolve, Dr. Greenhouseb�s team has been an advocate of broad molecular surveillance and developing methods that can adapt to changing technology, information, and questions relevant for public health and research.

To pursue their objective, Dr. Greenhouse has developed a modular community panel with Paragon Genomics, a panel that holds immense promise for decoding high value targets within the parasite genome to answer critical epidemiological questions surrounding malaria. With just a drop of blood collected onto filter paper, their team can answer multiple questions at scale. Their tireless efforts to take this technology forward and help investigators build the genomic surveillance infrastructure in malaria-endemic countries for this disease have great potential for transforming the landscape of malaria research.

To find out more, Paragon Genomics spoke with Dr. Greenhouse in the customer interview ahead.

Can you tell us about your background? How did you get interested in the topic of malaria?

Bryan Greenhouse (BG): I had always been fascinated by the use of genomics in studying the epidemiology in infectious disease. When I was interviewing for medical residency, I read a poster from Peter Small on the micro-epidemiology of tuberculosis. At that time, I was trying to decide between a career in laboratory or epidemiologic research for infectious disease. I was interested in how these modern technological tools could be leveraged to answer the questions of disease transmission. Over the course of my career, itb�s been amazing to see how much the technology has grown (both laboratory technology and the analytical capabilities) and how those two relate. In the last five years, I think web�ve reached a tipping point where the bottleneck is no longer computational tools and chemistry, but in the amount of effort we put in to develop working systems. Our lab, working closely with numerous wonderful collaborators, is thinking about how to implement and build out a system to perform surveillance more routinely, think more broadly, and answer questions about transmission in a scalable fashion.

paragon genomics

Dr. Hazel Gwarinda (Postdoc, National Institute for Communicable Diseases South Africa, bottom right) conducts malaria genomics training for the Translational Malaria Genomics (TraMGen) Fellows as part of the GenE8 projects (Genomics of Malaria in the E8).

In your opinion, what is a major challenge in genetically characterizing malaria parasites and how does your research address this?

BG: The main issue we faced was the tradeoff between throughput, number of targets, and sensitivity. Sensitivity is particularly challenging because of the sample quantity. We start with a spot of blood on filter paper so thereb�s not a lot of material in general, and most of the genetic material is from the human host. To compound the issue, there are often multiple strains of the parasite in a single infection and if you miss some of them, youb�re not necessarily getting the right answer. There are layers of complexity- the parasite DNA is the minority of the genetic material, we want to capture the variants of the pathogen DNA, and web�re attempting to answer multiple questions about drug resistance, diagnostic resistance (evading rapid diagnostic tests via a gene deletion), and transmission epidemiology. Our team was looking for an efficient and comprehensive solution to optimize on time and cost but not compromise on the quality of the data. We spent a couple of years researching and testing different technologies, but we couldnb�t find one that worked for both sensitivity and throughput until we met Paragon Genomics. After we kicked off a pilot project with Paragon, we were very impressed with the quality of the preliminary results. Once we established proof of principle and saw we could consistently generate quality data with challenging samples, our team wanted to expand the panel, scale up and apply this method at different sites globally. Customization was a key highlight. We went through many iterations of design, and the Paragon team was very open to working with us and able to get us what we needed in terms of a comprehensive and modular panel. The result is that now we have a method that does exactly what we need. And it is robust enough that the panel meets the needs of other labs and other countries.

What questions are you looking to answer and what are the goals of this program?

BG: Web�re mainly looking at drug resistance, diagnostic resistance, and transmission epidemiology. An important research focus recently has been on developing new tools to better measure various aspects of transmission, including overall transmission intensity and more detailed questions such as whether malaria cases are locally transmitted or imported. This aligns well with our broader mission at the Experimental and Population-based Pathogen Investigation Center (EPPIcenter) at UCSF to perform high-quality research and answer questions relevant for public health. Equally as important is our mission to train the next generation of scientists. We focus on that locally and globally in our work with international partners. Right now, we have three collaborative projects with training components active in Africa- one across six countries in Southern Africa, another in Mozambique, and a third in Uganda.

paragon genomics

Maria Florinda Victor Joao, a technical officer in the Angolan National Malaria Control Programme participates in a practical malaria genomics training at the National Institutes for Communicable Diseases in Johannesburg in March 2023.

Are there limitations of current gold standards or other methods, and how did Paragon Genomicsb� custom targeted sequencing approach help with that?

BG: The primary limitation of other methods we have evaluated is sensitivity- web�ve tried FLASH (CRISPR-based method), which worked to some extent. However, the design process was difficult, sensitivity was limited, and the chemistry wasnb�t robust- it was difficult for us to understand why certain targets were working better than others. Our lab also tried using molecular inversion probes, which had UMIs and allowed for overlapping segments in the same tube, without worrying about primer dimers. Similar to Paragonb�s chemistry, it allowed us to design for many targets, but the main limitation was sensitivity. There was essentially only a single cycle for capture, compared to the 10-15 cycles for multiplex PCR (mPCR). In the past, when I was working with microsatellites, I developed my own b�homebrewb� mPCR and designed my own primers, but it was difficult to expand the number of targets. And because we had such a robust solution out-of-the-box with Paragon, it was much more efficient for us to continue with a proven strategy.

paragon genomics

Maria Florinda Victor Joao, a technical officer in the Angolan National Malaria Control Programme participates in a practical malaria genomics training at the National Institutes for Communicable Diseases in Johannesburg in March 2023.

How did you approach the panel design process? How did you develop the b�modularb� approach and what advantages does it offer?

BG: AndrC)s Aranda-DC-az (Assistant Researcher) was the one who initially proposed a modular approach with different primer pools based on the application (drug and diagnostic resistance or transmission and population genetics) – he asked, why waste your sequencing reads on a question youb�re not interested in answering? But we also wanted to maintain the flexibility to pool primers together if we did want to investigate multiple questions simultaneously.

So we developed these modular primer pools that would allow us to customize by use case- we can use one pool for each and require fewer reads or combine two together and investigate a larger number of targets. We ended up developing several sizes for the drug resistance primer pools as well, one which is smaller and more sensitive but covers the most important targets, and a larger one which contains additional experimental targets for research purposes. Web�ll continue to refine the primer pools and informatic tools, pending new content web�d like to add, but this is a great starting tool for understanding population genetics, transmission dynamics, etc.

What do you see as the biggest advantages of using a custom targeted NGS panel for malaria research or diagnosis, and how does your panel maximize those benefits?

BG: The biggest advantage is probably the reliability of the workflow. Maybe there are other methods out there that are as simple but thereb�s something to be noted about the consistent data quality from Paragonb�s chemistry. We havenb�t needed to repeat many experiments or throw out data from many samples, which happened more frequently with the other methods we tried. The high uniformity of balance between targets and samples and high sensitivity have been big advantages. Web�re working on automation right now, and hope that it will make processing a large number of samples even easier.

How is the data looking? Are there any exciting discoveries you can share with us?

BG: Ib�d love to refer people to a pre-print that we released based on a colleagueb�s study in Ethiopia. The Horn of Africa is currently experiencing a triple-threat for malaria: drug and diagnostic resistant parasites being spread by an invasive mosquito, Anopheles stephensii. Our collaborators saw a surge in malaria cases and wanted to understand what precipitated such an outbreak and if there were any concerning mutations in the spreading parasites. Our collaborators sent samples from the field to our lab because we had this modular panel that could answer many questions in parallel. We were able to uncover with the sequencing data that the outbreak originated from just a few genetically distinct parasites that appeared to spread like wildfire by Anopheles stephensii. Data from the diversity module of the panel demonstrated that the outbreak essentially consisted of two clones. We discovered one of these clones had gene deletions associated with diagnostic resistance, consistent with these infections being missed by rapid diagnostic tests, and drug resistance for one of the most important classes of malaria medications (artemisinins). The multipurpose targeted NGS panel we developed with Paragon enabled us to efficiently determine these details about the epidemiology and drug resistance all at once.

How do you see NGS panels evolving in the field of malaria research and clinical practice and how do you think your panel will contribute to that evolution?

BG: We want to continue to have easy and small panels for existing applications. Web�ve also been thinking about something called therapeutic efficacy studies- when we evaluate if a malaria drug works, we treat patients and then follow them for many weeks. But if a patient comes back a few weeks later with a reinfection, you need to know if the infection is the original infection (indicating they failed therapy) or if itb�s an entirely new infection, indicating the drug worked well and the patient happened to get infected again. We need to identify if the parasites are the same or different. Itb�s been difficult because of the cumbersome methods in the past, but amplicon sequencing would be very useful in this application, particularly given the high sensitivity to detect most of the parasites present and the ability to simultaneously evaluate a number of diverse targets. As we think about leveraging the current panel and tailoring it for specific therapeutic efficacy studies, we want to statistically curate a subset of the panel (e.g. ~20 targets) for the most efficient sequencing. Our team has also been thinking about investigating interesting biological questions like how immunity develops. We want to sequence those malaria targets of the human immune system where genetic variation exists and examine associations with infection outcomes in our cohort studies and the associated immune response.

Whatb�s next for your team? Are there any plans to improve or expand the panel? How do you anticipate the technology to evolve in the coming years?

BG: We see a lot of potential with long-read technology, especially as it gets more accurate and less expensive. I think itb�s particularly relevant in some African sites since the sequencer is so portable and affordable- thereb�s no need for large capital equipment. We are also really interested to study regions and genes relevant to immunity, but they are frequently longer than the 300-600 bases which can be read with current short-read sequencing. Of particular interest are var genes in malaria (variant surface antigens), which can be a few thousand bases long and difficult to assemble with short-read sequencing as thereb�s a lot of diversity and mitotic recombination. I foresee us continuing to evolve panels, learning from our experience and developing panels for specific use cases and specific users, instead of a one-size-fits-all approach.

Could you share any anecdotes or stories that illustrate the impact of your research?

BG: The trainees are super excited! We first talked about the technology conceptually, specifically why we opted for NGS instead of qPCR. As theyb�ve gotten hands-on training, and have generated good libraries themselves, itb�s empowered them. They see how simple the workflow is, and as they generate the data, they see itb�s within their reach.

This latest training in South Africa and seeing the team be able to get everything up and running in two weeks in Gambia has been so rewarding. The more routine this type of work becomes, the more we can work as a community, and build tools to share the results. Ultimately web�d like to build towards contributing data to regional or global repositories like we have for COVID-19, a resource which has been so valuable.

Our team has started a monthly online seminar series with all current users (National Institute for Communicable Diseases South Africa, Infectious Diseases Research Collaboration Uganda, Centro de InvestigaC’C#o em SaC:de de ManhiC’a, MoC’ambique, Instituto de Salud Global Spain, Medical Research Council Unit The Gambia, National TsingHua University Taiwan, Yale University USA) to create community and enhance collaborations. And web�re actively working on finding other ways to have forums where they can discuss results, roadblocks and ideas, and troubleshoot together.

paragon genomics

Dr. Blazenka Letinic (Postdoc, NICD, center left) conducts malaria genomics training for the Translational Malaria Genomics (TraMGen) Fellows. Picture shows TraMGen Fellows from different regions in Africa.


  1. Centers for Disease Control and Prevention. (n.d.). Malaria worldwide: Impact of malaria. Retrieved July 17, 2023, from https://www.cdc.gov/malaria/malaria_worldwide/impact.html
  2. Center for Disease and Control. June 26, 2023. Locally acquired malaria cases identified in the US. https://emergency.cdc.gov/han/2023/han00494.asp


  1. Bioinformatics: Nick Hathaway, Max Murphy, Inna Gerlovina, Brian Palmer
  2. AndrC)s Aranda-DC-az, UCSF Assistant Researcher
  3. Jessica Briggs, UCSF Assistant Professor, P.I. for IMMRSE-U: Implementing Malaria Molecular Surveillance in Uganda.
  4. Jennifer Smith, UCSF Associate Professor and Senior Research Scientist at the Malaria Elimination Initiative (MEI), P.I. of GenE8: Genomics of Malaria in the E8, in collaboration with the Elimination Eight Initiative (E8).
  5. Collaborators in Africa: Jaishree Raman (NICD South Africa), Issac Ssewanyana (IDRC, Uganda), Alfredo Mayor (ISGlobal, Spain, and CISM, Mozambique)

Malaria Customer Spotlight File Request